Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
0.849
-0.014 (-1.59%)
At close: Apr 28, 2026, 4:00 PM EDT
0.898
+0.049 (5.72%)
After-hours: Apr 28, 2026, 7:01 PM EDT
Vivos Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 17.44 | 15.03 | 13.8 | 16.02 | 16.89 | |
| Revenue Growth (YoY) | 16.05% | 8.91% | -13.87% | -5.10% | 29.23% | |
| Cost of Revenue | 6.9 | 6.01 | 5.53 | 6.01 | 4.28 | |
| Gross Profit | 10.54 | 9.02 | 8.27 | 10.02 | 12.6 | |
| Selling, General & Admin | 29.13 | 19.61 | 24.95 | 34.18 | 31.34 | |
| Research & Development | - | - | - | 0.2 | - | |
| Operating Expenses | 30.44 | 20.19 | 25.57 | 35.05 | 32.08 | |
| Operating Income | -19.89 | -11.17 | -17.3 | -25.03 | -19.47 | |
| Interest Expense | - | - | - | - | -0.01 | |
| Other Non Operating Income (Expenses) | -1.34 | 0.04 | 3.71 | -0.1 | 0.11 | |
| EBT Excluding Unusual Items | -21.23 | -11.14 | -13.58 | -25.13 | -19.38 | |
| Asset Writedown | - | - | - | - | -0.91 | |
| Other Unusual Items | - | - | - | 1.29 | - | |
| Pretax Income | -21.23 | -11.14 | -13.58 | -23.85 | -20.29 | |
| Earnings From Continuing Operations | -21.23 | -11.14 | -13.58 | -23.85 | -20.29 | |
| Minority Interest in Earnings | 0.06 | - | - | - | - | |
| Net Income | -21.17 | -11.14 | -13.58 | -23.85 | -20.29 | |
| Net Income to Common | -21.17 | -11.14 | -13.58 | -23.85 | -20.29 | |
| Shares Outstanding (Basic) | 10 | 5 | 1 | 1 | 1 | |
| Shares Outstanding (Diluted) | 10 | 5 | 1 | 1 | 1 | |
| Shares Change (YoY) | 104.66% | 311.68% | 32.46% | 8.39% | 65.00% | |
| EPS (Basic) | -2.06 | -2.22 | -11.14 | -25.90 | -23.89 | |
| EPS (Diluted) | -2.06 | -2.22 | -11.14 | -25.90 | -23.89 | |
| Free Cash Flow | -17.6 | -13.26 | -12.8 | -20.51 | -18.13 | |
| Free Cash Flow Per Share | -1.71 | -2.64 | -10.50 | -22.28 | -21.35 | |
| Gross Margin | 60.44% | 60.00% | 59.93% | 62.52% | 74.65% | |
| Operating Margin | -114.05% | -74.32% | -125.32% | -156.21% | -115.31% | |
| Profit Margin | -121.37% | -74.09% | -98.42% | -148.81% | -120.15% | |
| Free Cash Flow Margin | -100.92% | -88.21% | -92.74% | -128.00% | -107.38% | |
| EBITDA | -18.59 | -10.59 | -16.68 | -24.36 | -18.74 | |
| EBITDA Margin | -106.55% | -70.45% | -120.82% | -152.03% | -110.97% | |
| D&A For EBITDA | 1.31 | 0.58 | 0.62 | 0.67 | 0.73 | |
| EBIT | -19.89 | -11.17 | -17.3 | -25.03 | -19.47 | |
| EBIT Margin | -114.05% | -74.32% | -125.32% | -156.21% | -115.31% | |
| Revenue as Reported | 17.44 | 15.03 | 13.8 | 16.02 | 16.89 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.